Hao-Jie Zhu

List of Publications by Year
in descending order

87	2,911	147801 31	182427 51
papers	citations	h-index	g-index

89	89	89	3414
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Two CES1 Gene Mutations Lead to Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular Basis. American Journal of Human Genetics, 2008, 82, 1241-1248.	6.2	202
2	Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 665-672.	2.5	160
3	Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 850-857.	2.5	157
4	Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology, 2006, 187, 415-423.	3.1	110
5	Berberine promotes glucagon-like peptide-1 (7â€“36) amide secretion in streptozotocin-induced diabetic rats. Journal of Endocrinology, 2009, 200, 159-165.	2.6	101
6	Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanism. Life Sciences, 2004, 75, 1313-1322.	4.3	91
7	Risperidone and Paliperidone Inhibit P-Glycoprotein Activity In Vitro. Neuropsychopharmacology, 2007, 32, 757-764.	5.4	84
8	Age- and Sex-Related Expression and Activity of Carboxylesterase 1 and 2 in Mouse and Human Liver. Drug Metabolism and Disposition, 2009, 37, 1819-1825.	3.3	83
9	Activation of the Antiviral Prodrug Oseltamivir Is Impaired by Two Newly Identified Carboxylesterase 1 Variants. Drug Metabolism and Disposition, 2009, 37, 264-267.	3.3	75
10	Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochemical Pharmacology, 2016, 119, 76-84.	4.4	72
11	An Assessment of Pharmacokinetics and Antioxidant Activity of Free Silymarin Flavonolignans in Healthy Volunteers: A Dose Escalation Study. Drug Metabolism and Disposition, 2013, 41, 1679-1685.	3.3	71
12	Long-Term Consequences of Methamphetamine Exposure in Young Adults Are Exacerbated in Glial Cell Line-Derived Neurotrophic Factor Heterozygous Mice. Journal of Neuroscience, 2007, 27, 8816-8825.	3.6	66
13	Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochemical Pharmacology, 2009, 77, 1266-1272.	4.4	64
14	Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. Drug Metabolism and Disposition, 2020, 48, 230-244.	3.3	62
15	Label-free absolute protein quantification with data-independent acquisition. Journal of Proteomics, 2019, 200, 51-59.	2.4	60
16	Sertraline and Its Metabolite Desmethylsertraline, but not Bupropion or Its Three Major Metabolites, Have High Affinity for P-Glycoprotein. Biological and Pharmaceutical Bulletin, 2008, 31, 231-234.	1.4	57
17	Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation. Drug Metabolism and Disposition, 2016, 44, 554-559.	3.3	54
18	Pharmacokinetics of Olanzapine After Single-Dose Oral Administration of Standard Tablet Versus Normal and Sublingual Administration of an Orally Disintegrating Tablet in Normal Volunteers. Journal of Clinical Pharmacology, 2006, 46, 164-171.	2.0	53

#	Article	IF	Citations
19	Antipsychotic Drugs Inhibit the Function of Breast Cancer Resistance Protein. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 336-341.	2.5	51
20	Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action. Pharmacological Research, 2012, 65, 491-496.	7.1	51
21	Genome-wide pQTL analysis of protein expression regulatory networks in the human liver. BMC Biology, 2020, 18, 97.	3.8	49
22	Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: Potential sources of metabolic drug interactions. Toxicology, 2010, 270, 59-65.	4.2	46
23	The Effects of Milk Thistle (Silybum marianum) on Human Cytochrome P450 Activity. Drug Metabolism and Disposition, 2014, 42, 1611-1616.	3.3	46
24	Population pharmacokinetic analysis of drugâ€“drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology, 2006, 183, 490-499.	3.1	43
25	Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behavioural Pharmacology, 2007, 18, 39-51.	1.7	42
26	Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes. Drug Metabolism and Pharmacokinetics, 2018, 33, 133-140.	2.2	42
27	A sensitive LCâ€“MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 902, 1-9.	2.3	41
28	Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophrenia Research, 2009, 110, 90-94.	2.0	35
29	Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. Journal of Neurochemistry, 2010, 114, 142-149.	3.9	34
30	Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatographyâ€“tandem mass spectrometry: Application to human ethanol interactions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 783-788.	2.3	34
31	Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 555-561.	2.5	33
32	A novel HPLC fluorescence method for the quantification of methylphenidate in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 858, 91-95.	2.3	32
33	Limitations of In Vitro Assessments of the Drug Interaction Potential of Botanical Supplements. Planta Medica, 2012, 78, 1421-1427.	1.3	31
34	Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein. European Journal of Pharmacology, 2008, 578, 148-158.	3.5	30
35	Comparative Proteomics Analysis of Human Liver Microsomes and S9 Fractions. Drug Metabolism and Disposition, 2020, 48, 31-40.	3.3	30
36	Sensitive quantification of atomoxetine in human plasma by HPLC with fluorescence detection using 4-(4,5-diphenyl-1H-imidazole-2-yl) benzoyl chloride derivatization. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 846, 351-354.	2.3	29

#	Article	IF	Citations
37	Antidepressive properties of microglial stimulation in a mouse model of depression induced by chronic unpredictable stress. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 101, 109931.	4.8	28
38	Prediction and In Vitro Evaluation of Selected Protease Inhibitor Antiviral Drugs as Inhibitors of Carboxylesterase 1: A Potential Source of Drug-Drug Interactions. Pharmaceutical Research, 2012, 29, 972-982.	3.5	27
39	Data-independent acquisition (DIA): An emerging proteomics technology for analysis of drug-metabolizing enzymes and transporters. Drug Discovery Today: Technologies, 2021, 39, 49-56.	4.0	26
40	Acetaminophen-Induced Liver Injury Alters Expression and Activities of Cytochrome P450 Enzymes in an Age-Dependent Manner in Mouse Liver. Drug Metabolism and Disposition, 2020, 48, 326-336.	3.3	25
41	‹b›Targeted absolute quantitative proteomics with SILAC internal standards and unlabeled fullâ€length protein calibrators (TAQSI)‹/b›. Rapid Communications in Mass Spectrometry, 2016, 30, 553-561.	1.5	24
42	A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms. Drug Metabolism and Disposition, 2017, 45, 1149-1155.	3.3	24
43	Absolute Quantitation of Drug-Metabolizing Cytochrome P450 Enzymes and Accessory Proteins in Dog Liver Microsomes Using Label-Free Standard-Free Analysis Reveals Interbreed Variability. Drug Metabolism and Disposition, 2019, 47, 1314-1324.	3.3	24
44	Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study. Clinical Pharmacology and Therapeutics, 2014, 96, 713-722.	4.7	23
45	Carboxylesterase 1-Mediated Drugâ€“Drug Interactions between Clopidogrel and Simvastatin. Biological and Pharmaceutical Bulletin, 2015, 38, 292-297.	1.4	22
46	Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study. Biochemical Pharmacology, 2017, 131, 89-97.	4.4	21
47	Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)-Based Proteomics of Drug-Metabolizing Enzymes and Transporters. Molecules, 2020, 25, 2718.	3.8	21
48	Reversal of P-Glycoprotein Mediated Multidrug Resistance in K562 Cell Line by a Novel Synthetic Calmodulin Inhibitor, E6. Biological and Pharmaceutical Bulletin, 2005, 28, 1974-1978.	1.4	20
49	Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method. Journal of Proteome Research, 2018, 17, 3606-3612.	3.7	20
50	THE ROLE OF THE POLYMORPHIC EFFLUX TRANSPORTER P-GLYCOPROTEIN ON THE BRAIN ACCUMULATION OF d-METHYLPHENIDATE AND d-AMPHETAMINE. Drug Metabolism and Disposition, 2006, 34, 1116-1121.	3.3	19
51	Enantiospecific gas chromatographicâ€“mass spectrometric analysis of urinary methylphenidate: Implications for phenotyping. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 862, 140-149.	2.3	19
52	Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus. Pharmacogenetics and Genomics, 2016, 26, 197-207.	1.5	18
53	Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2017, 37, 419-428.	1.4	16
54	Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation. European Journal of Clinical Pharmacology, 2013, 69, 733-734.	1.9	13

#	Article	IF	Citations
55	The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping. Pharmacogenetics and Genomics, 2014, 24, 381-386.	1.5	13
56	Functional Study of Carboxylesterase 1 Protein Isoforms. Proteomics, 2019, 19, e1800288.	2.2	13
57	Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. Biochemical Pharmacology, 2020, 180, 114127.	4.4	13
58	Intranasal lipopolysaccharide administration prevents chronic stress-induced depression- and anxiety-like behaviors in mice. Neuropharmacology, 2021, 200, 108816.	4.1	13
59	A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants. Pharmacogenetics and Genomics, 2012, 22, 215-218.	1.5	12
60	CES1P1 variant â^'816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. European Journal of Clinical Pharmacology, 2016, 72, 681-687.	1.9	11
61	Effect of E6, a novel calmodulin inhibitor, on activity of P-glycoprotein in purified primary cultured rat brain microvessel endothelial cells. Acta Pharmacologica Sinica, 2003, 24, 1143-9.	6.1	11
62	Isopropylphenidate: An Ester Homolog of Methylphenidate with Sustained and Selective Dopaminergic Activity and Reduced Drug Interaction Liability. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 648-654.	1.3	9
63	A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of valacyclovir and its metabolite acyclovir in mouse and human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1092, 447-452.	2.3	9
64	Chemoproteomic Identification of Serine Hydrolase RBBP9 as a Valacyclovir-Activating Enzyme. Molecular Pharmaceutics, 2020, 17, 1706-1714.	4.6	9
65	Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy. ACS Pharmacology and Translational Science, 2021, 4, 870-887.	4.9	9
66	A liquid chromatography/tandem mass spectrometry assay for the analysis of atomoxetine in human plasma and in vitro cellular samples. Biomedical Chromatography, 2012, 26, 1364-1370.	1.7	8
67	An ex vivo approach to botanicalâ€“drug interactions: A proof of concept study. Journal of Ethnopharmacology, 2015, 163, 149-156.	4.1	7
68	Consequences of Phenytoin Exposure on Hepatic Cytochrome P450 Expression during Postnatal Liver Maturation in Mice. Drug Metabolism and Disposition, 2018, 46, 1241-1250.	3.3	7
69	Biliary Excretionâ€“Mediated Food Effects and Prediction. AAPS Journal, 2020, 22, 124.	4.4	7
70	Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection. Pharmaceutics, 2021, 13, 1656.	4.5	7
71	Potential Regulation of UGT2B10 and UGT2B7 by miR-485-5p in Human Liver. Molecular Pharmacology, 2019, 96, 674-682.	2.3	6
72	Effect of CES1 genetic variation on enalapril steadyâ€state pharmacokinetics and pharmacodynamics in healthy subjects. British Journal of Clinical Pharmacology, 2021, 87, 4691-4700.	2.4	5

#	Article	IF	Citations
73	Developing a SWATH capillary LC-MS/MS method for simultaneous therapeutic drug monitoring and untargeted metabolomics analysis of neonatal plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1179, 122865.	2.3	5
74	Crataegus Special Extract WS 1442 Effects on eNOS and microRNA 155. Planta Medica, 2018, 84, 1094-1100.	1.3	4
75	Effect of biphenyl hydrolase-like (BPHL) gene disruption on the intestinal stability, permeability and absorption of valacyclovir in wildtype and Bphl knockout mice. Biochemical Pharmacology, 2018, 156, 147-156.	4.4	4
76	Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers. Clinical and Translational Science, 2021, 14, 1380-1389.	3.1	4
77	An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. Neuropsychiatric Disease and Treatment, 2011, 7, 501.	2.2	3
78	FRACPREDâ€2Dâ€PRM: A Fraction Prediction Algorithmâ€Assisted 2D Liquid Chromatographyâ€Based Parallel Reaction Monitoringâ€Mass Spectrometry Approach for Measuring Lowâ€Abundance Proteins in Human Plasma. Proteomics, 2020, 20, 2000175.	2.2	3
79	Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proofâ€ofâ€Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism. Clinical Pharmacology and Therapeutics, 2022, 111, 878-885.	4.7	3
80	Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy. Pharmacogenomics, 2017, 18, .	1.3	2
81	Effects of Overexpression of Fibroblast Growth Factor 15/19 on Hepatic Drug Metabolizing Enzymes. Drug Metabolism and Disposition, 2022, 50, 468-477.	3.3	2
82	Contributions of Cathepsin A and Carboxylesterase 1 to the Hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis. Drug Metabolism and Disposition, 2022, 50, 243-248.	3.3	1
83	Response to the Comments on â€œDetermining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Proteomics Methodâ€. Journal of Proteome Research, 2019, 18, 1458-1459.	3.7	0
84	Transcriptional Regulation of Carboxylesterase 1 in Human Liver: Role of the Nuclear Receptor Subfamily 1 Group H Member 3 and Its Splice Isoforms. Drug Metabolism and Disposition, 2022, 50, 43-48.	3.3	0
85	Shortâ€and Longâ€term Effects of Phenytoin Exposure on the Liver Proteome of Neonatal and Adult Mice Using SWATHâ€MS Technology. FASEB Journal, 2018, 32, 563.2.	0.5	0
86	Physiologically-based pharmacokinetic modeling to predict methylphenidate exposure affected by interplay among carboxylesterase 1 pharmacogenetics, drug-drug interactions, and sex. Journal of Pharmaceutical Sciences, 2022, , .	3.3	0
87	Genomeâ€Wide Association Study for the Genetic Determinants of Thiopurine Sâ€Methyltransferase Protein Expression in the Liver. FASEB Journal, 2022, 36, .	0.5	0